Louisiana State Employees Retirement System Invests $223,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Louisiana State Employees Retirement System bought a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 11,700 shares of the company’s stock, valued at approximately $223,000.

Several other institutional investors have also recently added to or reduced their stakes in ITOS. BlackRock Inc. raised its holdings in iTeos Therapeutics by 106.5% during the first quarter. BlackRock Inc. now owns 3,331,313 shares of the company’s stock worth $107,203,000 after purchasing an additional 1,718,085 shares in the last quarter. State Street Corp lifted its position in iTeos Therapeutics by 124.3% in the first quarter. State Street Corp now owns 1,711,891 shares of the company’s stock valued at $55,089,000 after acquiring an additional 948,540 shares during the last quarter. Vanguard Group Inc. boosted its stake in iTeos Therapeutics by 39.1% in the first quarter. Vanguard Group Inc. now owns 1,476,042 shares of the company’s stock valued at $47,499,000 after acquiring an additional 415,232 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of iTeos Therapeutics by 146.7% during the second quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company’s stock worth $11,522,000 after purchasing an additional 332,625 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of iTeos Therapeutics by 276.9% in the 2nd quarter. AQR Capital Management LLC now owns 445,110 shares of the company’s stock valued at $9,169,000 after purchasing an additional 327,025 shares during the last quarter.

iTeos Therapeutics Stock Down 1.3 %

NASDAQ:ITOS opened at $18.95 on Friday. The company has a market capitalization of $674.15 million, a PE ratio of 2.75 and a beta of 1.38. iTeos Therapeutics, Inc. has a 52-week low of $16.21 and a 52-week high of $41.00. The stock’s 50 day moving average price is $19.70 and its 200 day moving average price is $21.09.

iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last announced its earnings results on Thursday, November 10th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). The business had revenue of $19.49 million for the quarter, compared to analysts’ expectations of $42.05 million. iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. As a group, sell-side analysts anticipate that iTeos Therapeutics, Inc. will post 2.85 EPS for the current fiscal year.

About iTeos Therapeutics

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.